Combining Statins & Ezetimibe to Lower LDL - Quick Reference Sheet

Combining Statins & Ezetimibe to Lower LDL

Created on 09/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Adding ezetimibe to a statin lowers cholesterol several times more than doubling the statin dose. In people who have artery or kidney disease the pairing prevents some heart attacks, strokes and procedures; whether anyone lives longer remains disputed. A moderate statin plus ezetimibe produces fewer dose reductions and abandonments than a maximal statin alone, at equal protection. (Full Review)

Protocol

Standard regimen
Rosuvastatin 10 mg or atorvastatin 20 mg + ezetimibe 10 mg
Fixed 1:1 ratio, once daily with no staggering, as one fixed-dose tablet or two separate tablets.
Time of day
Any consistent hour
Atorvastatin, rosuvastatin, pitavastatin and ezetimibe; simvastatin, lovastatin and fluvastatin in the evening.
Single versus split dosing
Both components once daily
Splitting offers no advantage and reduces adherence; alternate-day rosuvastatin is salvage only.
Time to effect
LDL falls measurably
Within 2 weeks
The added 15% to 25% reduction from ezetimibe begins to register.
LDL steady state
4 to 6 weeks
Retesting before this point is uninformative.
Event reduction
Years, not months
Accrues over years and is never felt.

Benefits

Contraindications
  • Pregnancy, attempted conception, and breastfeeding
  • Active liver disease, or unexplained persistent transaminase elevation above 3× the upper limit of normal
  • Moderate or severe liver impairment (Child-Pugh Class B or C)
  • Documented prior rhabdomyolysis or immune-mediated necrotising myopathy on any statin
  • Known hypersensitivity to either component
  • Concurrent strong CYP3A4 inhibitor therapy (clarithromycin, itraconazole, ritonavir, verapamil, diltiazem) where a simvastatin- or lovastatin-based combination cannot be substituted
Key Interactions
  • Cyclosporine (immune-suppressing transplant medication)
  • Gemfibrozil and other fibrates
  • Bile acid sequestrants (cholestyramine, colesevelam)
  • Warfarin and vitamin K antagonists
  • Over-the-counter agents (grapefruit juice, high-dose niacin, antacids)
  • Red yeast rice
  • Supplements with additive LDL-lowering effects (plant sterols, berberine, psyllium, bergamot)
  • Other interventions (PCSK9 inhibitors, bempedoic acid)

Risk & Side Effects

  • High: Muscle symptoms and myopathy; new-onset type 2 diabetes; liver enzyme elevation
  • Medium: Gastrointestinal symptoms
  • Low: Cancer incidence, hemorrhagic stroke, cognitive complaints
  • Speculative: Consequences of sustained very low LDL

Monitoring

Marker Target Why
LDL cholesterol Below 70 mg/dL with plaque, 100 mg/dL otherwise; many specialists target 55 mg/dL after an event The primary target the combination exists to move
Apolipoprotein B Below 80 mg/dL; 60 mg/dL with plaque Counts artery-damaging particles, not the cholesterol inside them
Lipoprotein(a) Below 30 mg/dL, equivalently below 75 nmol/L Largely unmoved by this combination, so it reframes residual risk
Non-HDL cholesterol Below 100 mg/dL; 85 mg/dL with plaque Captures every artery-damaging particle when triglycerides are high
Triglycerides Below 100 mg/dL Contextualises LDL; flags insulin resistance
ALT and AST ALT below 25 U/L in men, below 20 U/L in women Transaminase rise both components can cause
Creatine kinase No established target; track against own pre-treatment value Separates statin myopathy from unrelated aches
HbA1c 4.8% to 5.4% The statin component's modest push toward type 2 diabetes
hs-CRP Below 1.0 mg/L Residual inflammatory risk after LDL is lowered, which the statin only partly reduces
TSH 0.5 to 2.5 mIU/L Undertreated hypothyroidism raises LDL and predisposes to muscle symptoms
eGFR and creatinine eGFR above 90 mL/min/1.73 m² Sets the rosuvastatin dose ceiling and contextualises the kidney-disease evidence
25-hydroxyvitamin D 40 to 60 ng/mL Low levels track with reported statin muscle complaints

Cadence: Lipids and liver enzymes at 4 to 12 weeks and after every dose change, then every 6 to 12 months once the target holds. HbA1c annually, twice yearly where fasting glucose is already prediabetic. Creatine kinase only when muscle symptoms appear. Lipoprotein(a) once in a lifetime.

Qualitative Assessment

  • Muscle comfort after unaccustomed exertion, recorded as a daily score rather than recalled
  • Exercise capacity and recovery time, which neither component is expected to change
  • Digestive pattern in the first eight weeks, when ezetimibe symptoms appear and usually resolve
  • Sleep quality and dream intensity after any switch to or from a fat-soluble statin
  • Confidence in adherence, since missed doses explain more target failures than pharmacology